| Dr Justin Daniels, MD | |
|
3901 Rainbow Blvd, Mail Stop 1034, Kansas City, KS 66160-7415 | |
| (913) 588-9900 | |
| Not Available |
| Full Name | Dr Justin Daniels |
|---|---|
| Gender | Male |
| Speciality | Critical Care (intensivists) |
| Experience | 12 Years |
| Location | 3901 Rainbow Blvd, Kansas City, Kansas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1336409572 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207LC0200X | Anesthesiology - Critical Care Medicine | 04-39778 (Kansas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Kansas Hospital | Kansas city, KS | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Kansas University Physicians, Inc. | 8921911587 | 1456 |
News Archive
Results of a new study conducted in St. Petersburg, Russia, show that decreasing HIV transmission among Russian HIV-infected drinkers will require creative and innovative approaches.
BioSante Pharmaceuticals, Inc., today announced additional positive safety data in its ongoing LibiGel Phase III clinical development program. For the second time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study. Based on this review, the DMC once again unanimously recommended continuation of the study as described in the FDA-agreed LibiGel safety study protocol, with no modifications.
A new study involving data from more than 20,000 individuals has uncovered several DNA sequences linked to impaired pulmonary function. The research, an analysis that combined the results of several smaller studies, provides insight into the mechanisms involved in reaching full lung capacity.
LifeCycle Pharma A/S today reported that the company's lead product candidate, LCP-Tacro, successfully demonstrated non-inferiority compared to tacrolimus in its Phase III trial, Study 3001.
› Verified 1 days ago
| Entity Name | Kansas University Physicians, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003858333 PECOS PAC ID: 8921911587 Enrollment ID: O20040401000328 |
News Archive
Results of a new study conducted in St. Petersburg, Russia, show that decreasing HIV transmission among Russian HIV-infected drinkers will require creative and innovative approaches.
BioSante Pharmaceuticals, Inc., today announced additional positive safety data in its ongoing LibiGel Phase III clinical development program. For the second time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study. Based on this review, the DMC once again unanimously recommended continuation of the study as described in the FDA-agreed LibiGel safety study protocol, with no modifications.
A new study involving data from more than 20,000 individuals has uncovered several DNA sequences linked to impaired pulmonary function. The research, an analysis that combined the results of several smaller studies, provides insight into the mechanisms involved in reaching full lung capacity.
LifeCycle Pharma A/S today reported that the company's lead product candidate, LCP-Tacro, successfully demonstrated non-inferiority compared to tacrolimus in its Phase III trial, Study 3001.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Justin Daniels, MD 3901 Rainbow Blvd, Mail Stop 1034, Kansas City, KS 66160-7415 Ph: (913) 588-9900 | Dr Justin Daniels, MD 3901 Rainbow Blvd, Mail Stop 1034, Kansas City, KS 66160-7415 Ph: (913) 588-9900 |
News Archive
Results of a new study conducted in St. Petersburg, Russia, show that decreasing HIV transmission among Russian HIV-infected drinkers will require creative and innovative approaches.
BioSante Pharmaceuticals, Inc., today announced additional positive safety data in its ongoing LibiGel Phase III clinical development program. For the second time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study. Based on this review, the DMC once again unanimously recommended continuation of the study as described in the FDA-agreed LibiGel safety study protocol, with no modifications.
A new study involving data from more than 20,000 individuals has uncovered several DNA sequences linked to impaired pulmonary function. The research, an analysis that combined the results of several smaller studies, provides insight into the mechanisms involved in reaching full lung capacity.
LifeCycle Pharma A/S today reported that the company's lead product candidate, LCP-Tacro, successfully demonstrated non-inferiority compared to tacrolimus in its Phase III trial, Study 3001.
› Verified 1 days ago
Lyna Rehan, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 3901 Rainbow Blvd # Ms 1034, Kansas City, KS 66160 Phone: 913-588-3304 Fax: 913-588-3365 | |
Dr. Joel Kent Grigsby, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Kansas City, KS 66160 Phone: 913-588-3315 | |
O. Layton Alldredge Jr., MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: Kansas University Medical Ctr, 3901 Rainbow Blvd Ms 1034, Kansas City, KS 66160 Phone: 913-588-3304 | |
Timothy Sowder, Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: Kumc 3901 Rainbow Blvd Ms 1034, Kansas City, KS 66160 Phone: 913-588-3302 Fax: 913-588-3365 | |
Robert P Devine, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 3901 Rainbow Blvd, Kansas City, KS 66160 Phone: 913-588-3315 | |
Jennifer B Kenny, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Mail Stop 1034, Kansas City, KS 66160 Phone: 913-588-3315 Fax: 913-588-3365 | |
Dr. Sarafina Kristine Kankam, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3901 Rainbow Blvd, Kansas City, KS 66160 Phone: 913-588-5000 |